SCHEMBL22766396

SCHEMBL22766396

C=Cc1cc2nccc(Oc3cc(F)c(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)c2cc1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 17/20 0.60
▸ MET P08581 12/20 0.60
▸ KDR P35968 3/20 0.60
▸ MERTK Q12866 8/20 0.57
▸ NTRK1 P04629 2/20 0.56
▸ TEK Q02763 2/20 0.56
▸ FLT1 P17948 2/20 0.56
▸ AURKB Q96GD4 2/20 0.56
▸ AURKA O14965 1/20 0.56
▸ RIPK2 O43353 1/20 0.56
▸ ABCB11 O95342 1/20 0.56
▸ ABL1 P00519 1/20 0.56
▸ EGFR P00533 1/20 0.56
▸ ERBB2 P04626 1/20 0.56
▸ LCK P06239 1/20 0.56
▸ PGR P06401 1/20 0.56
▸ LYN P07948 1/20 0.56
▸ RET P07949 1/20 0.56
▸ CHRM2 P08172 1/20 0.56
▸ HCK P08631 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22766207 0.93 AXL (0.61) AXLMETKDRMERTKNTRK1
SCHEMBL22766365 0.91 MET (0.73) AXLMETKDRMERTKNTRK1
SCHEMBL22766186 0.88 AXL (0.74) AXLMETKDRMERTKNTRK1
SCHEMBL22766341 0.88 AXL (0.63) AXLMETKDRMERTKNTRK1
SCHEMBL21201014 0.87 AXL (0.68) AXLMETKDRMERTKNTRK1
SCHEMBL21200764 0.86 AXL (0.67) AXLMETKDRMERTKNTRK1
SCHEMBL21200573 0.86 AXL (0.79) AXLMETKDRMERTKNTRK1
SCHEMBL371830 0.85 AXL (0.82) AXLMETKDRMERTKNTRK1
SCHEMBL29693478 0.85 AXL (0.82) AXLMETKDRMERTKNTRK1
SCHEMBL22766364 0.84 MET (0.74) AXLMETKDRMERTKNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230043835-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2023-02-09 — — US disclosed
WO-2020247418-A1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS EXELIXIS, INC. (US) 2020-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230043835-A1 Compounds for the Treatment of Kinase-Dependent Disorders MAP3K20, MAP3K6, MAP3K1 AXL 946/4885MET 668/4885KDR 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback